Neurofibromatosis 1
Drug research and approvals for neurofibromatosis 1: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 43 studies of neurofibromatosis 1 are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and the EU has 2 authorised medicines for it.
- Recruiting worldwide: 43
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 2
- Observational Study of the Real-world Effectiveness and Safety of Selumetinib Treating Adult Patients With…NCT07888517 · Not reported · AstraZeneca · starts Sep 28, 2026
- Cognitive Intervention for Children and Adolescents With NF1NCT07869914 · Not applicable · The Hospital for Sick Children · starts Oct 13, 2026
- Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated…NCT07407803 · Phase 3 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · starts Mar 31, 2026
- Mirdametinib in Patients With Advanced NF1-mutant MelanomaNCT07237100 · Phase 2 · Kevin Kim, MD · starts Oct 13, 2025
- Tailoring an Online Platform to Promote Evidence-Based Care for Adults With Neurofibromatosis 1 and Low Health LiteracyNCT07233408 · Not applicable · Massachusetts General Hospital · starts Dec 28, 2025
- Prevalence, Clinical Characteristics, Progression, and Management of Neurofibromatosis Type 1 in Egypt (NF1-Egy)NCT07221331 · Not reported · AstraZeneca · starts Nov 19, 2025
- Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1NCT07102394 · Phase 1 · Johns Hopkins University · starts Feb 1, 2026
- Clinical and Demographic Characteristics of Adult p Atients With NEurofibromatosis in RUSsiaNCT07088991 · Not reported · AstraZeneca · starts Jun 6, 2025
- PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform NeurofibromasNCT06961565 · Phase 1 · Pasithea Therapeutics Corp. · starts May 30, 2025
Approved 1
- SelumetinibDual specificity mitogen-activated protein kinase kinase 1 inhibitor
Phase 2 12 of 16
- LovastatinHMG-CoA reductase inhibitor
- Aminolevulinic acidDNA inhibitor
- Pirfenidone
- AcetylcysteineGlutathione precursor
- CelecoxibCyclooxygenase-2 inhibitor
- EverolimusFK506-binding protein 1A inhibitor
- LamotrigineSodium channel alpha subunit blocker
- MethotrexateDihydrofolate reductase inhibitor
- SirolimusFK506-binding protein 1A inhibitor
- TemozolomideDNA inhibitor
- Peginterferon alfa-2bInterferon alpha/beta receptor agonist
- VincristineTubulin inhibitor
Phase 1 or earlier 3
- Polidocanol
- Deoxycholic acidCell membrane disrupting agent
- AbemaciclibCyclin-dependent kinase 4 inhibitor
How its trials ended
215 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 37 whose ending is known, 35% met their primary endpoint, 11% missed it and 54% stopped early.
- Completed, result not reported8941%
- Ongoing6932%
- Status unknown209%
- Met its primary endpoint136%
- Stopped: other or unclear94%
- Stopped: enrollment or feasibility84%
- Missed its primary endpoint42%
- Stopped: sponsor or business decision21%
- Stopped: lack of efficacy1<1%
| Jul 17, 2025 | EzmeklyMirdametinib · orphan | Merck Europe B.V. | EMA ↗ |
| Jun 17, 2021 | KoselugoSelumetinib · orphan | AstraZeneca AB | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA